Calliditas Therapeutics: Q4 Comment
Redeye notes that the Q4 report from Calliditas did not include any surprises. We provide a brief comment on the financials and highlight the most important events during the period. Our Base case remains at SEK250 per share - providing significant upside potential from current levels.